BriaCell

1880 Century Park East, Suite #315
Los Angeles
California
90067
United States

Show jobs for this employer

39 articles with BriaCell

  • Overall Survival of 13.3 months inpatients,including 14 months in patients with Grade I/II tumors, suggesting clinical benefit;

  • BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (" BriaCell " or the "Company") (TSX-V:BCT) (OTCQB:BCTXF ) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in a poster session on December 9 – 11 during the 2020 San Antonio Breast Cancer Symposium ® (SABCS), a virtual event. The po

  • BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer.

  • BriaCell Therapeutics Corp. is announcing that Dr. Bill Williams, BriaCell’s President & CEO, will be presenting at the 3rd Annual Biologics World Nordic 2020 Conference, a virtual event held during September 30 – October 1, 2020.

  • BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that it has received a research grant from the Wiseman Cancer Research Foundation, a 501c(3) nonprofit organization based in Beverly Hills, CA. The research grants are awarded to individual scientists or en

  • BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining compositions and methods of developing novel multi-valent decoy receptors for diagnosis and treatment of coronavirus infection.

  • Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, with or without a PD-1 inhibitor. Patients with “moderately” or “well” differentiated tumors showed a higher rate of dis

  • BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Dr. Bill Williams, BriaCell’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a virtual event, will be held on June 25 - 26, 2020.

  • Preliminary safety and efficacy data is being presented on May 29 at 9:00 a.m. ET from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: Lead candidate, Bria-IMT™, with or without a PD-1 inhibitor, showed no serious side effects and resulted in clinical responses in heavily pre-treated patients with metastatic breast cancer. Women with “moderately” or “well” differentiated tumors showed a higher rate of disease contr

  • BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining a novel vaccine platform to selectively deliver antigens of interest to immune cells to induce immune responses toward pathogens including SARS-CoV-2 virus or cancer cells, or reduce immune responses in the case of autoimmune or allergic diseases.

  • BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO).

  • Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
  • BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the development and use of novel therapeutics that activate immune cells to selectively destroy the cancer cells or to selectively block cancer cells from inactivating immune cells.

  • Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
  • BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining certain features thought to expand the clinical applications of BriaCell’s genetically engineered whole-cell immunotherapies to those of infectious diseases including the SARS-CoV-2 virus that causes Coronavirus Disease 2019.

  • BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining certain features thought to expand the clinical applications of BriaCell’s genetically engineered whole-cell immunotherapies to those of infectious diseases including the SARS-CoV-2 virus that causes Coronavirus Disease 2019.

  • Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
  • BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has been selected to present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally planned in-person Annual Meeting.

  • Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. Clinical and immune activity of Bria-IMT™, alone or in combination with checkpoint inhibitors,  KEYTRUDA ® and INCMGA00012, in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting, postponed to August 2020. BERKELEY, Calif. and VA

  • A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.